GB202005617D0 - Improved t cell manufacturing process - Google Patents

Improved t cell manufacturing process

Info

Publication number
GB202005617D0
GB202005617D0 GBGB2005617.2A GB202005617A GB202005617D0 GB 202005617 D0 GB202005617 D0 GB 202005617D0 GB 202005617 A GB202005617 A GB 202005617A GB 202005617 D0 GB202005617 D0 GB 202005617D0
Authority
GB
United Kingdom
Prior art keywords
improved
manufacturing process
cell manufacturing
cell
manufacturing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2005617.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adaptimmune Ltd
Original Assignee
Adaptimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptimmune Ltd filed Critical Adaptimmune Ltd
Priority to GBGB2005617.2A priority Critical patent/GB202005617D0/en
Publication of GB202005617D0 publication Critical patent/GB202005617D0/en
Priority to JP2022562606A priority patent/JP7760524B2/ja
Priority to EP21721165.5A priority patent/EP4136216A1/en
Priority to PCT/GB2021/050909 priority patent/WO2021209759A1/en
Priority to CN202180029152.2A priority patent/CN115397975A/zh
Priority to CA3175266A priority patent/CA3175266A1/en
Priority to US18/046,874 priority patent/US20230133064A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB2005617.2A 2020-04-17 2020-04-17 Improved t cell manufacturing process Ceased GB202005617D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2005617.2A GB202005617D0 (en) 2020-04-17 2020-04-17 Improved t cell manufacturing process
JP2022562606A JP7760524B2 (ja) 2020-04-17 2021-04-16 改善されたｔ細胞製造プロセス
EP21721165.5A EP4136216A1 (en) 2020-04-17 2021-04-16 Improved t cell manufacturing process
PCT/GB2021/050909 WO2021209759A1 (en) 2020-04-17 2021-04-16 Improved t cell manufacturing process
CN202180029152.2A CN115397975A (zh) 2020-04-17 2021-04-16 改进的t细胞制备方法
CA3175266A CA3175266A1 (en) 2020-04-17 2021-04-16 Improved t cell manufacturing process
US18/046,874 US20230133064A1 (en) 2020-04-17 2022-10-14 T cell manufacturing process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2005617.2A GB202005617D0 (en) 2020-04-17 2020-04-17 Improved t cell manufacturing process

Publications (1)

Publication Number Publication Date
GB202005617D0 true GB202005617D0 (en) 2020-06-03

Family

ID=70859978

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2005617.2A Ceased GB202005617D0 (en) 2020-04-17 2020-04-17 Improved t cell manufacturing process

Country Status (7)

Country Link
US (1) US20230133064A1 (https=)
EP (1) EP4136216A1 (https=)
JP (1) JP7760524B2 (https=)
CN (1) CN115397975A (https=)
CA (1) CA3175266A1 (https=)
GB (1) GB202005617D0 (https=)
WO (1) WO2021209759A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US11851471B2 (en) 2017-01-09 2023-12-26 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
EP4211149A4 (en) 2020-09-09 2024-10-09 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF
CN116496283B (zh) * 2022-01-18 2024-04-19 中国药科大学 五氮杂苊类化合物、制备方法、药物组合物和应用
JP2025515473A (ja) * 2022-04-28 2025-05-15 キュー バイオファーマ， インコーポレイテッド 改変された細胞傷害性ｔ細胞およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3151672T1 (sl) * 2014-06-06 2021-03-31 Bluebird Bio, Inc. Izboljšani T-celični sestavki
EP3364969A4 (en) * 2015-10-20 2019-07-10 Kite Pharma, Inc. METHOD FOR THE PRODUCTION OF T CELLS FOR T CELL THERAPY
WO2017070042A1 (en) * 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
US20180320133A1 (en) * 2015-11-05 2018-11-08 City Of Hope Methods for preparing cells for adoptive t cell therapy

Also Published As

Publication number Publication date
US20230133064A1 (en) 2023-05-04
WO2021209759A1 (en) 2021-10-21
EP4136216A1 (en) 2023-02-22
CN115397975A (zh) 2022-11-25
JP2023521875A (ja) 2023-05-25
CA3175266A1 (en) 2021-10-21
JP7760524B2 (ja) 2025-10-27

Similar Documents

Publication Publication Date Title
GB202005617D0 (en) Improved t cell manufacturing process
IL276600A (en) Methods for producing T cells
SG11202104183RA (en) Process for producing genetically engineered t cells
GB202005216D0 (en) Cell
EP4152463A4 (en) PROCESS FOR PRODUCING SOLID ELECTROLYTE
IL276472A (en) A process for producing CAR-T cells in a closed system
GB202007321D0 (en) T cells
ZA202211411B (en) Cell
GB201911958D0 (en) Methods of t cell production
SG11202104994PA (en) Improved t cell manufacturing process
GB202008642D0 (en) Electrohemical cell
SG11202101098YA (en) Cell production method
GB202018651D0 (en) Lithium-selenium cell
IL311786A (en) hypoimmune cells
GB201915803D0 (en) Cell production
GB202111742D0 (en) Improved process
GB2602623B (en) Bio-LPG production process
GB202012991D0 (en) Cell culture processes
GB201919073D0 (en) Novel manufacturing process
GB202300914D0 (en) Manufacturing process
IL288136A (en) Production process of double-sided photovoltaic cells
PL3878611T3 (pl) Częściowo zautomatyzowana komórka produkcyjna
GB202311671D0 (en) Biofuel production process
IL319979A (en) ALOGABAT production process
EP4435096A4 (en) CELL PRODUCTION PROCESS

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)